A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults With Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs TRX 518 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GITR Inc; Leap Therapeutics
- 13 Nov 2017 According to a Leap Therapeutics media release, patient follow-up, biopsy, and biomarker analysis of this trial are ongoing.
- 11 Aug 2017 Status changed from recruiting to active, no longer recruiting, as reported in a Leap Therapeutics media release.
- 11 Aug 2017 According to a Leap Therapeutics media release, the company has completed dose escalation phase and fully enrolled the expansion cohort of this trial.